Reta glucagon-like peptide-1 (GLP-1) trizepatide receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies operate by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents boost insulin release and suppress

The management of diabetes continues to evolve with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant attention. These medications offer promising approaches for controlling blood sugar levels and potentially improve the lives of individuals living with diabetes